ADA Updates Standards of Medical Care in Diabetes

Share this content:
ADA Updates Standards of Medical Care in Diabetes
ADA Updates Standards of Medical Care in Diabetes

TUESDAY, March 14, 2017 (HealthDay News) -- The American Diabetes Association (ADA) recommends metformin as first-line therapy for type 2 diabetes, according to a synopsis of the 2017 ADA Standards of Medical Care in Diabetes published online March 14 in the Annals of Internal Medicine.

James J. Chamberlain, M.D., from St. Mark's Hospital and St. Mark's Diabetes Center in Salt Lake City, and colleagues reviewed the literature to add, clarify, and revise recommendations for the diagnosis and management of patients with diabetes based on new evidence and to update the ADA Standards of Medical Care.

The authors note that metformin is safe, effective, and inexpensive, and is associated with a reduced risk of cardiovascular events and death in patients with diabetes; metformin is recommended as the first-line treatment for type 2 diabetes and should be initiated at the time of diagnosis for most patients. Another treatment option should be considered for patients who do not tolerate or have contraindications to metformin. Initiation of dual combination therapy should be considered to more quickly achieve a target hemoglobin A1c (HbA1c) level for patients with a level of 9.0 percent or greater who are not acutely symptomatic. If the HbA1c target has not been achieved within about three months of therapy initiation, therapy should be intensified.

"This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »